title: 5-Carboxamido-tryptamine, CP-122,288 and dihydroergotamine but not sumatriptan, CP-93,129, and serotonin-5-O-carboxymethyl-glycyl -tyrosinamide block dural plasma protein extravasation in knockout mice that lack 5-hydroxytryptamine1B receptors.
abstract: We studied the dural plasma protein extravasation response after unilateral electrical stimulation of the trigeminal ganglion in mice lacking serotonin 5-HT1B (5-HT1D beta) receptors by modifying a technique previously described in rats or guinea pigs. We investigated the inhibitory effects of six 5-HT1 receptor agonists in this model: 3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one (CP-93,129), sumatriptan, serotonin-5-O-carboxymethyl-glycyl -tyrosinamide (GTI), 5-methylaminosulfonylmethyl-3-(N-methylpyrrolidin-2R -ylmethyl)-1H-indole (CP-122,288), 5-carboxamido-tryptamine (5-CT), and dihydroergotamine. The plasma extravasation response did not differ between wild-type and mutant after vehicle injection. The potency of sumatriptan, CP-122,288, CP-93,129, and 5-CT in wild-type mice was similar to that previously reported for rats. CP-122,288 (1 nmol kg), 5-CT (1 nmol/kg), and dihydroergotamine (72 nmol/kg) inhibited plasma protein extravasation within dura mater after electrical trigeminal ganglion stimulation in both wild-type and knockout mice, which suggests that these agonists act predominantly via receptors other than 5-HT1B. Unlike the wild-type mice, CP-93,129 (1.4 mumol/kg), a specific 5-HT1B receptor agonist, had no effect in knockout mice. The same held true for sumatriptan (0.7 mumol/kg) and GTI (0.6 mumol/kg). These results suggest that CP-93,129, sumatriptan, and GTI exert their effects via 5-HT1B (5-HT1D beta) receptors in mice.
authors.affiliation: Massachusetts General Hospital, Harvard Medical School, Charlestown 02129, USA.
authors.forename: X J
authors.initials: XJ
authors.lastname: Yu
authors.forename: C
authors.initials: C
authors.lastname: Waeber
authors.forename: N
authors.initials: N
authors.lastname: Castanon
authors.forename: K
authors.initials: K
authors.lastname: Scearce
authors.forename: R
authors.initials: R
authors.lastname: Hen
authors.forename: J E
authors.initials: JE
authors.lastname: Macor
authors.forename: J
authors.initials: J
authors.lastname: Chauveau
authors.forename: M A
authors.initials: MA
authors.lastname: Moskowitz
authors.forename: J
authors.initials: J
authors.lastname: Chaveau
mesh_terms: D000818:Animals; D002199:Capillary Permeability / Q000187:drug effects; D004087:Dihydroergotamine / Q000494:pharmacology*; D004151:Dipeptides / Q000494:pharmacology*; D051379:Mice; D018345:Mice, Knockout; D011725:Pyridines / Q000494:pharmacology*; D011758:Pyrroles / Q000494:pharmacology*; D011759:Pyrrolidines / Q000494:pharmacology*; D011985:Receptors, Serotonin / Q000187:drug effects*; D012701:Serotonin / Q000031:analogs & derivatives* / Q000494:pharmacology; D017366:Serotonin Receptor Agonists / Q000494:pharmacology*; D018170:Sumatriptan / Q000031:analogs & derivatives* / Q000494:pharmacology*; D012668:Trigeminal Ganglion / Q000187:drug effects*
chemical_list: D004151:Dipeptides; D011725:Pyridines; D011758:Pyrroles; D011759:Pyrrolidines; D011985:Receptors, Serotonin; D017366:Serotonin Receptor Agonists; C065046:3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo(3,2-b)pyrid-5-one; C072128:serotonin-O-carboxymethyl-Gly-Tyr; C085263:CP 122288; D012701:Serotonin; D004087:Dihydroergotamine; D018170:Sumatriptan; C047087:5-carboxamidotryptamine